|
|
||||||||
From the Departments of Neurology (Drs. Ferriby, de Seze, Stojkovic, Destée, and Vermersch), Internal Medicine (Drs. Hachulla and Hatron), and Pneumology (Dr. Wallaert), CHRU de Lille, France.
Address correspondence and reprint requests to Dr. D. Ferriby, Clinique Neurologique, Service de Neurologie D, Hôpital Roger Salengro, CHRU Lille, 59037 Lille Cedex; e-mail: d-ferriby{at}chru-lille.fr
The authors evaluated the long-term clinical outcome of neurosarcoidosis and determined predictive factors of disease course. Twenty-seven patients with neurosarcoidosis were followed for at least 5 years from the onset of neurologic symptoms. Patients with CNS involvement during the course of the disease had a higher Modified Oxford Handicap Scale score than those with peripheral nervous system involvement (p < 0.02). CNS involvement may be a predictive factor for a less favorable disease course. Early and intensive treatment should be considered in such cases.
This article has been cited by other articles:
![]() |
M. Moravan and B. M. Segal Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil Neurology, January 27, 2009; 72(4): 337 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Scott, K. Yandora, A. Valeri, C. Chieffe, and C. Schramke Aggressive Therapy for Neurosarcoidosis: Long-term Follow-up of 48 Treated Patients Arch Neurol, May 1, 2007; 64(5): 691 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Baumann and W. C. Robertson Jr Neurosarcoid Presents Differently in Children Than in Adults Pediatrics, December 1, 2003; 112(6): e480 - 486. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |